​​​The Princess Margaret Lymphoma and Myeloma Site Group is linked with the largest autologous stem cell transplant and radiation medicine programs in Canada. This, combined with our cutting-edge diagnostics, radiation therapy planning and delivery, technology and highly skilled staff, means that our patients receive world-class care across all our programs.​

Amyloidosis Program

The Princess Margaret has developed a focus on the management of light-chain amyloidosis, a specific type of amyloidosis related to plasma cell dyscrasias. Our inter-professional team of pathologists, hematologists, surgeons and registered dietitians work together to monitor for amyloid deposits in body tissues.

With some of the most comprehensive, cutting-edge chemotherapy, stem cell transplant and clinical research programs in Canada, our team can offer a coordinated approach to treatment that includes clinical trials.

Blood & Marrow Transplant Program

The largest blood and marrow transplant program in Canada, our inter-professional team of medical, nursing and allied health staff work together to integrate patient care, research and education to improve transplant outcomes for people with hematological disorders such as leukemia, lymphoma, myeloma, severe aplastic anemia, germ cell disorders and other plasma cell disorders.

Our Blood and Marrow Transplant Program offers allogeneic and autologous transplant services to patients. Our team of hematologists and medical oncologists, specialized oncology and apheresis nurses, nurse practitioners and other allied health professionals work collaboratively with each patient’s health care team, including consulting with other Princess Margaret services such as pathology, pharmacy and psychosocial supports where necessary.

Our team has dedicated expertise in the coordination of related and unrelated donor-recipient matches using OneMatch with Canadian Blood Services, the US National Marrow Donor Program and the international collaborative World Marrow Donor Program.

Matched donors donate anonymously by traditional bone marrow harvest or by an apheresis collection process that collects peripheral stem cells or hematopoietic progenitor cells (HPC) for transplantation.

Our centre includes an outpatient Apheresis Centre and in-house, outpatient bone marrow harvesting, as well as access to the Phillip S. Orsino Cell Therapy facility, where cells are stored and treated to ensure the removal of any disease.

Our physician-scientists, advanced oncology nurses and laboratory services are at the forefront of innovating techniques in peripheral stem cell/HPC transplants, including prophylaxis and treatment of graft-vs-host disease, stem cell telemedicine for remote physician and nurse practices and advancing patient safety and research.

Lymphoma Clinic

As a comprehensive cancer centre, Princess Margaret is able to assess and then plan and deliver treatment for people with lymphoproliferative disorders, including the lymphomas (non-Hodgkin's and Hodgkin's lymphoma and chronic lymphocytic leukemia).

Every year our group sees over 500 people with lymphoma, including 80 to 90 people with Hodgkin's lymphoma. We also provide consultation on autologous stem cell transplantation for close to 150 patients and perform about 50 transplants per year, many in the context of clinical trials addressing improvements in treatment.

Our radiation oncologists are leaders in developing and implementing radiation treatment approaches that optimize the balance between tumour control and sparing normal, healthy tissues to help minimize late effects through image-guided and intensity-modulated radiation therapy.

We are also leaders in clinical trials research and conduct many studies of new agents in lymphoma from "first in human" studies of novel targeted treatment to combination studies aimed at changing the standard of care for newly diagnosed and recurrent lymphomas.

Members of the lymphoma group are internationally recognized leaders in the study of late effects of cancer treatment in both children and adults. Our research includes causes and prevention of leukemia after stem cell transplantation, second malignancies and cardiovascular disease after curative radiation of Hodgkin's lymphoma, and the long-term effect of lymphoma treatment on fertility.

Learn more about the Lymphoma Clinic »

Multiple Myeloma Clinic

With nearly 400 new patients every year, the Princess Margaret Myeloma Program sees the most patients with newly diagnosed or recurrent multiple myeloma in Canada.

We perform 180 to 200 autologous stem cell transplants (including double or "tandem" transplants) each year. With the largest stem cell transplant program in Canada, we are able to accept referrals for transplant as a standard of care for appropriate patients, but also conduct these as part of clinical trials that reflect our commitment to advancing knowledge and best practices in multiple myeloma treatment.

Our innovative studies aim to identify the optimum pre-transplant indicators and post-transplant treatment strategies to improve long-term disease control and survival.

Advanced diagnostic capabilities help our physicians to identify important genetically defined myeloma subtypes, allowing better assignment of novel and standard treatments. By exploring myeloma biology, physicians in the Princess Margaret myeloma program have identified a number of important new therapeutic targets and helped develop novel agents currently being explored at other centres world-wide.

Learn more about the Multiple Myeloma Clinic »

https://www.uhn.ca/PrincessMargaret/Health_Professionals/Programs_Departments/Breast/Pages/clinical_programs.aspx
https://www.uhn.ca/PrincessMargaret/Education/Continuing_Education_Programs/Pages/continuing_education_programs.aspx
Last reviewed: 2/6/2018
Last modified: 10/30/2023 12:36 PM
Back to Top